Johnson & Johnson
JNJ
Below: live stock price for Johnson & Johnson (JNJ), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Johnson & Johnson (JNJ) is a Healthcare company based in United States. Operating in Drug Manufacturers - General, it employs about 138,200 people. Over the past year JNJ traded between 185.12 and 282.02 USD. Trailing P/E sits near 41.46 on a market cap of about 657.68B USD. It currently yields 1.96% in dividends.
- Prev close
- $275.20
- Volume (24h)
- $2.45B
- Market cap
- $657.68B
- Currency
- USD
Score
39/ 100 · Weak
- Value0
- Quality70
- Momentum64
- Growth19
- Risk72
- Dividend33
- Liquidity17
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 272.8079 -0.14%
- +20 bars
- 272.2677 -0.34%
- +60 bars
- 272.0591 -0.42%
- +120 bars
- 272.0514 -0.42%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: 1σ ≈ ±1.5% per bar.
Interpretation
Composite signals look weak. Strength: risk profile with weakness: valuation. Price sits near the upper third of the recent range, trend is roughly flat.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value0/100
Value looks fragile — driven by P/E (41.46).
P/E:41.46P/B:8.07PEG:3.07 - Quality70/100
Quality looks solid — driven by Gross margin (67.77%).
ROE:20.02%ROA:8.46%Profit margin:16.20%Gross margin:67.77% - Momentum64/100
Momentum looks solid — driven by 52w change (46.68%).
52w change:46.68% - Growth19/100
Growth looks fragile — driven by Earnings growth (-95.90%).
Revenue growth:5.90%Earnings growth:-95.90% - Risk72/100
Risk looks solid — driven by Debt / equity (54.77).
Beta:0.21Debt / equity:54.77Short interest:0.78% - Dividend33/100
Dividend looks weak — driven by Payout ratio (80.12%).
Dividend yield:1.96%Payout ratio:80.12% - Liquidity17/100
Liquidity looks fragile — driven by Current ratio (1.02).
Current ratio:1.02Quick ratio:0.65
Derived from public market data — informational, not investment advice.
Price report
How this asset has actually moved over the last 251 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 20.8%
- Max drawdown
- -11.0%
- Below period high
- -3.1%
- Best day
- +3.99%
- Worst day
- -5.73%
- Up days
- 54%
- Current streak
- 1 down
- Typical day swing
- 1.8%
- Volume vs average
- -0%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 282.02 high → 245.17 low · 60 bars
- ResistanceFib +161.8% extensionnot reached341.6433 USD+25.05% from current
- ResistanceFib +100% extensionnot reached318.87 USD+16.72% from current
- ResistanceFib +61.8% extensionnot reached304.7933 USD+11.56% from current
- ResistanceFib +27.2% extensionnot reached292.0432 USD+6.90% from current
- Current273.2 USD
- SupportFib 38.2% retracementtested 22×267.9433 USD-1.92% from current
- SupportFib 50% midpointtested 7×263.595 USD-3.52% from current
- SupportFib 61.8% retracementtested 13×259.2467 USD-5.11% from current
- SupportFib 78.6% retracementtested 7×253.0559 USD-7.37% from current
- SupportFib −27.2% extensionnot reached235.1468 USD-13.93% from current
- SupportFib −61.8% extensionnot reached222.3967 USD-18.60% from current
- SupportFib −100% extensionnot reached208.32 USD-23.75% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Financials
- 52w high
- $282.02
- 52w low
- $185.12
- 52w change
- 46.68%
- Day high
- $282.00
- Day low
- $273.15
- P/E (TTM)
- 41.46
- Forward P/E
- 23.52
- PEG
- 3.07
- Price / Book
- 8.07
- Beta (5Y)
- 0.21
- Enterprise value
- 685.1B
- EV / Revenue
- 6.9
- EV / EBITDA
- 19.86
- EPS (TTM)
- $6.59
- Forward EPS
- $11.62
- Dividend yield
- 1.96%
- Dividend rate
- $5.36
- Payout ratio
- 80.12%
- Revenue (TTM)
- 99.33B
- EBITDA
- 34.5B
- Free cash flow
- 18.5B
- Total cash
- 17.23B
- Total debt
- 44.65B
- Debt / Equity
- 54.77
- Current ratio
- 1.02
- Quick ratio
- 0.65
- Profit margin
- 16.20%
- Gross margin
- 67.77%
- Return on assets
- 8.46%
- Return on equity
- 20.02%
- Shares outstanding
- 2.41B
- Float
- 2.4B
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Analyst & Risk
Analysts' consensus via Yahoo Finance — not investment advice.
- Beta (vs S&P 500)
- 0.21
- very stable
- 52-week change
- 46.68%
- Short % of float
- 0.78%
- Short ratio (days)
- 2.23
- Debt / Equity
- 54.77
- very high leverage
- Current ratio
- 1.02
- Quick ratio
- 0.65
- ROE
- 20.02%
- ROA
- 8.46%
- PEG ratio
- 3.07
- EV / Revenue
- 6.9
- EV / EBITDA
- 19.86
- Revenue growth
- 5.90%
- Earnings growth
- -95.90%
- EBITDA
- 34.5B
- Free cash flow
- 18.5B
- Total cash
- 17.23B
- Total debt
- 44.65B
- Insider holdings
- 0.05%
- Institutional
- 76.78%
Recent rating changes
- 2026-10-16Wells FargoOverweight → Overweightmain
- 2026-10-15Morgan StanleyOverweight → Overweightmain
- 2026-10-14Leerink PartnersOutperform → Outperformmain
- 2026-10-14Wells FargoOverweight → Overweightmain
- 2026-10-14RBC CapitalOutperform → Outperformmain
- 2026-10-07GuggenheimBuy → Buyreit
- 2026-10-06RBC CapitalOutperform → Outperformmain
- 2026-10-05CitigroupBuy → Buymain
Financial documents
- Periodic Financial Reports10-Q2026-10-21
- Corporate Changes & Voting Matters8-K2026-10-13
- Annual Report of Proxy Voting Record of Registered Management Investment Companies filed on Form N-PXN-PX2026-08-11
- Corporate Changes & Voting Matters8-K2026-08-04
- Corporate Changes & Voting Matters8-K2026-07-29
- Corporate Changes & Voting Matters8-K2026-07-28
- Periodic Financial Reports10-Q2026-07-23
- Corporate Changes & Voting Matters8-K2026-07-15
- Annual report of employee stock purchase11-K2026-06-25
- Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)SD2026-05-27
- Corporate Changes & Voting Matters8-K2026-04-28
- Periodic Financial Reports10-Q2026-04-22
Recent news
- Suze Orman Says You Don’t Have to Buy Every Market Dip. Here’s Why24/7 Wall St.2 hr. ago
- Roth IRA vs. Taxable Account: How Much of $17,985 in Blue-Chip Dividends Would You Keep?24/7 Wall St.5 hr. ago
- If a Bear Market Is Coming, History Says These Stocks Could Be the Smartest to OwnMotley Fool6 hr. ago
- 3 Biotech Stocks With Upside Of Up To 80%Simply Wall St.16 hr. ago
- Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors.Motley Fool18 hr. ago
- Stryker Sinks 5% on Q3 Miss and Guidance Cut: “Fall Short of Our Expectations”TIKRyesterday
- How Investors Are Reacting To Johnson & Johnson Stock New Drug ProgressSimply Wall St.yesterday
- No Tricks, Just Treats: 3 Dividend Stocks With Payouts You Can Trust24/7 Wall St.yesterday
Related
Other assets in this category.
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.